Regeneron Pharmaceuticals, Inc. (REGN) stock
REGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 16/308% above fair value
$951.19−8.22 (-0.86%)
Close on Nov 12, 2026Market cap $98.40BP/E 21.0Yield –
Regeneron Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Regeneron Pharmaceuticals's operating margin for the twelve months ending Sep 30, 2026 was 28.8%. For fiscal 2025 it was 24.9%, against 28.1% the year before. The highest annual figure on record is 55.7% in fiscal 2021.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 24.9% | −3.2 |
| FY2024 | Dec 31, 2024 | 28.1% | −2.8 |
| FY2023 | Dec 31, 2023 | 30.9% | −8.1 |
| FY2022 | Dec 31, 2022 | 38.9% | −16.7 |
| FY2021 | Dec 31, 2021 | 55.7% | +13.6 |
| FY2020 | Dec 31, 2020 | 42.1% | +8.4 |
| FY2019 | Dec 31, 2019 | 33.7% | −15.6 |
| FY2018 | Dec 31, 2018 | 49.3% | +13.8 |
| FY2017 | Dec 31, 2017 | 35.4% | +8.0 |
| FY2016 | Dec 31, 2016 | 27.4% | −3.1 |
| FY2015 | Dec 31, 2015 | 30.5% | +1.3 |
| FY2014 | Dec 31, 2014 | 29.2% | −6.1 |
| FY2013 | Dec 31, 2013 | 35.3% | +2.1 |
| FY2012 | Dec 31, 2012 | 33.2% | +79.2 |
| FY2011 | Dec 31, 2011 | -46.0% | −24.8 |
| FY2010 | Dec 31, 2010 | -21.2% | −1.7 |
| FY2009 | Dec 31, 2009 | -19.5% | +16.6 |
| FY2008 | Dec 31, 2008 | -36.2% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 40.0% | +12.7 |
| Q2 FY2026 | Jun 30, 2026 | 30.1% | +0.8 |
| Q1 FY2026 | Mar 31, 2026 | 17.8% | −1.7 |
| Q4 FY2025 | Dec 31, 2025 | 22.7% | −3.5 |
| Q3 FY2025 | Sep 30, 2025 | 27.3% | −4.4 |
| Q2 FY2025 | Jun 30, 2025 | 29.4% | −0.8 |
| Q1 FY2025 | Mar 31, 2025 | 19.5% | −4.4 |
| Q4 FY2024 | Dec 31, 2024 | 26.1% | −2.2 |
| Q3 FY2024 | Sep 30, 2024 | 31.7% | −1.3 |
| Q2 FY2024 | Jun 30, 2024 | 30.2% | −2.0 |
| Q1 FY2024 | Mar 31, 2024 | 23.9% | −6.0 |
| Q4 FY2023 | Dec 31, 2023 | 28.3% | −5.3 |
| Q3 FY2023 | Sep 30, 2023 | 33.0% | −8.6 |
| Q2 FY2023 | Jun 30, 2023 | 32.2% | −6.7 |
| Q1 FY2023 | Mar 31, 2023 | 29.9% | −12.5 |
| Q4 FY2022 | Dec 31, 2022 | 33.6% | −19.7 |
| Q3 FY2022 | Sep 30, 2022 | 41.7% | −11.8 |
| Q2 FY2022 | Jun 30, 2022 | 38.8% | −26.3 |
| Q1 FY2022 | Mar 31, 2022 | 42.4% | −1.6 |
| Q4 FY2021 | Dec 31, 2021 | 53.3% | +5.1 |
| Q3 FY2021 | Sep 30, 2021 | 53.5% | +7.6 |
| Q2 FY2021 | Jun 30, 2021 | 65.1% | +31.5 |
| Q1 FY2021 | Mar 31, 2021 | 44.0% | +5.7 |
| Q4 FY2020 | Dec 31, 2020 | 48.2% | +11.9 |
| Q3 FY2020 | Sep 30, 2020 | 45.9% | +3.6 |
| Q2 FY2020 | Jun 30, 2020 | 33.6% | +13.6 |
| Q1 FY2020 | Mar 31, 2020 | 38.3% | +3.3 |
| Q4 FY2019 | Dec 31, 2019 | 36.3% | −1.0 |
| Q3 FY2019 | Sep 30, 2019 | 42.4% | +4.7 |
| Q2 FY2019 | Jun 30, 2019 | 20.0% | −18.7 |
| Q1 FY2019 | Mar 31, 2019 | 35.0% | −2.6 |
| Q4 FY2018 | Dec 31, 2018 | 37.2% | +3.2 |
| Q3 FY2018 | Sep 30, 2018 | 37.7% | +0.4 |
| Q2 FY2018 | Jun 30, 2018 | 38.7% | +1.3 |
| Q1 FY2018 | Mar 31, 2018 | 37.5% | +4.9 |
| Q4 FY2017 | Dec 31, 2017 | 34.1% | +5.8 |
| Q3 FY2017 | Sep 30, 2017 | 37.3% | – |
| Q2 FY2017 | Jun 30, 2017 | 37.4% | – |
| Q1 FY2017 | Mar 31, 2017 | 32.6% | – |
| Q4 FY2016 | Dec 31, 2016 | 28.3% | – |
See a number that looks wrong?